Announcements

Latest Announcements

Latest Announcements

Press Release

Woke and University of Sydney Sign Term Sheet for Phase II trial of WP002 Psilocybin in Alcohol Use Disorder

Read More
Press Release

Provisional Patent Application

Read More
Press Release

Woke and Swinburne University Sign Memorandum of Understanding to Develop WP002 Psilocybin-assisted Psychotherapy Phase IIB trial in Treatment-Resistant Depression

Read More
Press Release

Woke and QIMR Berghofer Sign Letter of Intent for Clinical Trial of WP002 Psilocybin in Prolonged Grief

Read More
Press Release

Woke Highlights Morgan Stanley Report on Psychedelics

Read More
Press Release

Woke and University of Western Australia collaborate to discover LSD analogues

Read More
Press Release

WokePh and Monash complete WP001 psilocybin formulation

Read More
Press Release

Woke Announces First Shipment of Natural Health Products from HAVN Life Sciences

Read More
Press Release

Woke Enters Clinical Agreement with Macquarie University for WP001 Low-dose Psilocybin for Moderate Depression

Read More
Press Release

Woke Signs Manufacturing Agreement with IDT Australia for Novel Psilocybin Formulations to Treat Depression

Read More
Press Release

Woke Expands Partnership with Monash University to Develop Novel Psilocybin Formulation for Treatment- Resistant Depression

Read More
Press Release

Woke Signs Letter of Intent with The University of Western Australia to Identify Novel LSD Analogues

Read More
Press Release

Woke Imports Psilocybin from Purisys in the US for Formulation of Novel Dosage Forms

Read More
Press Release

Woke Signs Letter of Intent with IDT Australia for Manufacture of Novel Psilocybin Dosage Forms

Read More
Press Release

Woke Pharmaceuticals Launches New Website

Read More
Press Release

Woke’s Response to TGA Decision to Maintain the Current Schedule 9 Classification for Psilocybin

Read More
Press Release

Woke Completes Oversubscribed $1.55m Seed Capital Raising to Develop Medicinal Psychedelics

Read More
Press Release

Woke Purchases Synthetic Psilocybin from Purisys for Formulation of Novel Dosage Forms

Read More
Press Release

Woke and HAVN Life Enter into Agreement to Distribute Natural Health Products in AU, NZ and China

Read More
Press Release

Woke Joins Medical Psychedelics Working Group of UK Drug Science

Read More
Press Release

Woke Collaborates with Monash University to Develop Novel Psilocybin Formulation for Moderate Depression

Read More

ACN: 651 290 729

Address: Suite 301, 10 Bridge St, Sydney NSW 2000 Australia

Email: info@wokeph.com